These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 8194731)

  • 41. Risk factors and current NSAID use.
    Simon LS
    J Rheumatol; 1999 Jul; 26(7):1429-31. PubMed ID: 10405924
    [No Abstract]   [Full Text] [Related]  

  • 42. From peptic ulcer disease to NSAID gastropathy. An evolving nosology.
    Roth SH
    Drugs Aging; 1995 May; 6(5):358-67. PubMed ID: 7647425
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Non-steroidal anti-inflammatory drugs induced gastropathy: endoscopic findings in rheumatic patients.
    Rodríguez W; Irrizarry JF; Latimer C
    Bol Asoc Med P R; 1988 Oct; 80(10):366-8. PubMed ID: 3265062
    [No Abstract]   [Full Text] [Related]  

  • 44. [2-nd place of Young Scientist's Competition. Basal prostaglandins level in stomach mucous as predictors of NSAID-gastropathy].
    Kim VA
    Eksp Klin Gastroenterol; 2009; (7):114-8. PubMed ID: 20469716
    [No Abstract]   [Full Text] [Related]  

  • 45. [Prevention of NSAID-induced gastric lesions: H2 antagonists or misoprostol? A meta-analysis of controlled clinical studies].
    Capurso L; Koch M
    Clin Ter; 1991 Dec 15-31; 139(5-6):179-89. PubMed ID: 1686995
    [No Abstract]   [Full Text] [Related]  

  • 46. [Secondary and primary prophylaxis of gastropathy associated with nonsteroidal antiinflammatory drugs or low-dose-aspirin: a review based on four clinical scenarios].
    Limmer S; Ittel TH; Wietholtz H
    Z Gastroenterol; 2003 Aug; 41(8):719-28. PubMed ID: 12910426
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [NSAID-gastropathy: state-of-the-art therapy optimization capabilities in outpatient practice].
    Burkov SG; Arutiunov AT; Gurova NIu; Lobanova EG; Nikiforov PA; Okoemov MN; Cherezova IN; Chugunnikova LI
    Eksp Klin Gastroenterol; 2008; (3):97-101. PubMed ID: 19145889
    [No Abstract]   [Full Text] [Related]  

  • 48. Clinically significant gastropathy associated with nonsteroidal antiinflammatory drug use in children with juvenile rheumatoid arthritis.
    Keenan GF; Giannini EH; Athreya BH
    J Rheumatol; 1995 Jun; 22(6):1149-51. PubMed ID: 7674245
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prevention of nonsteroidal anti-inflammatory drug-induced gastropathy: clinical and economic implications of a single-tablet formulation of diclofenac/misoprostol.
    Goldstein JL; Larson LR; Yamashita BD
    Am J Manag Care; 1998 May; 4(5):687-97. PubMed ID: 10179922
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Cytoprotective effect of rosaprostol during treatment with non-steroidal anti-inflammatory agents in arthrorheumatic pathologies].
    Cataldo MG; Sallì L; Scalici G; D'Aiuto A; Bongiorno A; Salerno L
    Minerva Dietol Gastroenterol; 1989; 35(3):191-4. PubMed ID: 2601868
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Importance of age and other risk factors in NSAID-induced gastropathy].
    Lee HL; Han DS; Kim JB; Kim JP; Jeon YC; Sohn JH; Hahm JS
    Korean J Gastroenterol; 2004 Nov; 44(5):246-51. PubMed ID: 15564803
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Gallic acid prevents nonsteroidal anti-inflammatory drug-induced gastropathy in rat by blocking oxidative stress and apoptosis.
    Pal C; Bindu S; Dey S; Alam A; Goyal M; Iqbal MS; Maity P; Adhikari SS; Bandyopadhyay U
    Free Radic Biol Med; 2010 Jul; 49(2):258-67. PubMed ID: 20406680
    [TBL] [Abstract][Full Text] [Related]  

  • 53. NSAID gastropathy: the second most deadly rheumatic disease? Epidemiology and risk appraisal.
    Fries JF
    J Rheumatol Suppl; 1991 Mar; 28():6-10. PubMed ID: 2038014
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Helicobacter pylori: a risk and severity factor of non-steroidal anti-inflammatory drug induced gastropathy.
    Heresbach D; Raoul JL; Bretagne JF; Minet J; Donnio PY; Ramée MP; Siproudhis L; Gosselin M
    Gut; 1992 Dec; 33(12):1608-11. PubMed ID: 1487160
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Non-steroid gastropathy combined with Helicobacter pylori: current problems].
    Akhmedov VA; Vinzhegina VA; Sudakova AN; Rozenblit EI
    Eksp Klin Gastroenterol; 2007; (1):64-6. PubMed ID: 17547117
    [No Abstract]   [Full Text] [Related]  

  • 56. The rise and decline of nonsteroidal antiinflammatory drug-associated gastropathy in rheumatoid arthritis.
    Fries JF; Murtagh KN; Bennett M; Zatarain E; Lingala B; Bruce B
    Arthritis Rheum; 2004 Aug; 50(8):2433-40. PubMed ID: 15334455
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Effectiveness, safety, and costs of measures for prevention of gastropathy due to the use of nonsteroidal antiinflammatory drugs].
    Salentijn GJ
    Ned Tijdschr Geneeskd; 1999 Nov; 143(46):2340. PubMed ID: 10589227
    [No Abstract]   [Full Text] [Related]  

  • 58. Rescue strategies against non-steroidal anti-inflammatory drug-induced gastroduodenal damage.
    Lim YJ; Lee JS; Ku YS; Hahm KB
    J Gastroenterol Hepatol; 2009 Jul; 24(7):1169-78. PubMed ID: 19682191
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Gastropathy caused by nonsteriod anti-inflammatory drugs: from understanding of development mechanisms to planning strategy of treatment and prophylaxis].
    Akhmedov VA; Vinzhegina VA; Sudakova AN; Rozenblit EI
    Ter Arkh; 2007; 79(2):81-5. PubMed ID: 17460975
    [No Abstract]   [Full Text] [Related]  

  • 60. Gastric effects of the novel non-steroidal anti-inflammatory drug amtolmetin guacyl.
    Coruzzi G; Bertaccini G
    Nutrition; 1999 Apr; 15(4):325-6. PubMed ID: 10319368
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.